anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Participants will have two study visits. During the first visit, participants will have an fMRI scan to identify the OPA location in each individual participant. During the second visit, participants will receive rTMS. Each visit lasts approximately 90 minutes.
Methods and kits for performing minimally invasive medical procedures are disclosed herein. In one embodiment, a kit includes a medicament including an enzyme, such as a serine protease having an ability to sensitize less than an ability to sensitize of chymopapain. The enzyme is configured to dissolve tissue within a nucleus of an intervertebral disc. A delivery device is included in the kit and is configured to be percutaneously inserted into the nucleus of an intervertebral disc and inject the medicament into the nucleus of the intervertebral disc. In some embodiments, the medicament includes subtilisin. In some embodiments, the serine protease has an antigenicity less than an antigenicity of chymopapain. A kit can also include a pressure sensor that is configured to measure a pressure within a nucleus of the intervertebral disc.
On smartphones, participants in this arm will receive twice daily and weekly prompts to report on behaviors under study and be able to send self-initiated event-contingent reports on behaviors under study. They will complete in-person assessments at enrollment, 30-days and study exit at 90-days.
Type 2 diabetes (T2D) constitutes a major public health problem, and despite prevention efforts, this pandemic disease is one of the deadliest diseases in the world. In 2022, 6.7 million patients with T2D died prematurely from vascular complications. Indeed, diabetes increases the risk of myocardial infarction or stroke eightfold. The identification of the molecular factors involved in the occurrence of cardiovascular complications and their prevention are therefore major axes. Our hypothesis is that factors brought into play during physiological aging appear prematurely with diabetes progression. Our study focused on the aging of the extracellular matrix (ECM), a major element in the maintenance of vascular homeostasis. We characterized the morphological and functional aspects of aorta, with a focus on the collagen and elastic fibers of diabetic mice aged from 6 mo to nondiabetic mice aged 6 mo and 20 mo. The comparison with the two nondiabetic models (young and old) highlighted an exacerbated activity of proteases, which could explain a disturbance in the collagen accumulation and an excessive degradation of elastic fibers. Moreover, the generation of circulating elastin-derived peptides reflects premature aging of the ECM. These extracellular elements contribute to the appearance of vascular rigidity, often the origin of pathologies such as hypertension and atherosclerosis. In conclusion, we show that diabetic mice aged 6 mo present the same characteristics of ECM wear as those observed in mice aged 20 mo. This accelerated aortic wall remodeling could then explain the early onset of cardiovascular diseases and, therefore, the premature death of patients with T2D.NEW & NOTEWORTHY Aortic elastic fibers of young (6-mo old) individuals with diabetes degrade prematurely and exhibit an appearance like that found in aged (20-mo old) nondiabetic mice. Exacerbated elastolysis and elastin-derived peptide production are characteristic elements, contributing to early aortic wall rigidity and hypertension development. Therefore, limiting this early aging could be a judicious therapeutic approach to reduce cardiovascular complications and premature death in patients with diabetes.
PURPOSE: A cosmetic composition containing natural products for contracting pores and suppressing sebum secretion is provided to effectively prevent pore enlargement. CONSTITUTION: A cosmetic composition for reducing pore size or suppress sebum secretion contains a Mentha arvensis L. var. piperascens MALINV. leaf extract and a wheat sprout extract as active ingredients, mixed in a weight ratio of 1-10:1-10. The extracts are prepared using water, alcohol of C1-C3, or a mixture thereof. The cosmetic composition is manufactured in the form of a cream, a skin softener, an astringent, a milk lotion, a foundation, a soap, or a cleansing foam. An external use pharmaceutical composition for treating and relieving acne contains 1-30 wt% of the extracts as active ingredients. [Reference numerals] (AA) Inhibition ratio(%); (BB) Embodiment 1; (CC) Embodiment 2; (DD) Embodiment 3; (EE) Embodiment 4; (FF) Embodiment 5; (GG) Positive control group
The invention relates to compositions for the induction of anti-IgE antibodies in order to prevent or inhibit IgE-mediated disorders. The compositions contain carriers foreign to the immunized human or animal coupled to polypeptides containing fragments of the IgE molecule. The fragment of the IgE molecule includes the constant CH1 and/or the CH4 domain of the IgE molecule. The composition is administered to humans or animals in order to induce antibodies specific for endogenous IgE antibodies. These induced anti-IgE antibodies reduce or eliminate the pool of free IgE in the serum. Since many allergic diseases are mediated by IgE, IgE-mediated disorders are ameliorated in treated mammals.
PURPOSE:To obtain a composition, containing a fermented milk or its treated substance as an active ingredient and capable of regulating interleukin productivity of human or animal cells without any toxicity and side effects. CONSTITUTION:A composition containing a fermented milk prepared by fermenting a milk ingredient such as whole milk of, e.g. animal milk or soybean milk, skim milk or whey with a lactic acid bacterium such as lactic acid- producing bacterium, e.g. Streptococcus thermophilus or Lactobacillus bulgaricus or the lactic acid bacterium and a yeast or its treated substance as an active ingredient. The aforementioned composition is capable of regulating interleukin productivity of human or animal cells, especially enhancing the interleukin-2 productivity or interleukin-3 productivity of the human or animal cells and/or suppressing interleukin-6 productivity. The fermented milk or its treated substance herein used has advantages in that living bodies are not adversely affected even by ingesting a large amount thereof. The composition may directly be used or added to a food to provide a functional food or health food.
Evaluate women for ectopic pregnancy if they become pregnant with Skyla in place because the likelihood of a pregnancy being ectopic is increased with Skyla. Approximately one-half of pregnancies that occur with Skyla in place are likely to be ectopic. Also consider the possibility of ectopic pregnancy in the case of lower abdominal pain, especially in association with missed menses or if an amenorrheic woman starts bleeding.

The incidence of ectopic pregnancy in clinical trials with Skyla, which excluded women with a history of ectopic pregnancy, was approximately 0.1% per year. The risk of ectopic pregnancy in women who have a history of ectopic pregnancy and use Skyla is unknown. Women with a previous history of ectopic pregnancy, tubal surgery or pelvic infection carry a higher risk of ectopic pregnancy. Ectopic pregnancy may result in loss of fertility.
There will be 7 cohorts in this study. In each cohort, participants will receive a single oral dose of a placebo while fasted/fed.
OBJECTIVE: Recently, it has been discussed whether or not mosaic embryo transfers should be performed since they might result in viable pregnancies, although they often end up being discarded. We report a case of successful pregnancy, after a mosaic embryo transfer from an in vitro matured egg and frozen PESA sperm.
CASE DESCRIPTION: Tests performed on a female aged 40 years and a male aged 37 years seeking fertility treatment found she had an adequate ovarian reserve and patent fallopian tubes. He had a history of cryptorchidism and inguinal hernia repair. The spermogram showed azoospermia, and testicular ultrasound showed an atrophic left testicle and a normal right testis. The vas deferens was palpated during physical examination. Intracytoplasmic sperm injection with percutaneous epididymal sperm aspiration (PESA) was indicated. Two cycles of IVF after controlled ovarian stimulation with follitropin delta was performed. In the first cycle, seven mature eggs were inseminated, two fertilized normally, resulting in one blastocyst biopsied and analyzed by NGS with complex aneuploid results. In the second cycle, frozen sperm from PESA was used. Three eggs were inseminated on the day of the procedure (resulting in 2 blastocysts), and three in vitro matured eggs were inseminated after 24 hours (resulting in 1 blastocyst). NGS analysis showed two complex aneuploid embryos and one 40% low-level trisomy 20 aneuploid mosaicism (+20) for the post 24-hour embryo. A mosaic embryo transfer was performed, resulting in clinical pregnancy and birth of a healthy baby girl with a normal blood karyotype.
DISCUSSION: Mosaic embryo transfer is a topic for discussion. Certain levels of mosaicism do not seem to pose risks to the development of the fetus.
With IRB approval, patients will be enrolled in a prospective clinical trial to assess outcomes in 2 cohorts of patients undergoing unicompartmental versus more extensive biologic OCA transplantation of the knee using MOPSTM-preserved allografts (including menisci), anatomically-shaped allografts, autogenous bone marrow aspirate concentrate (BMC)-treated donor bone, and treatment-specific postoperative rehabilitation. Demographic and operative data will be collected. Outcome assessments will include VAS pain, IKDC, SANE, Tegner and PROMIS Mobility for knee at 6 months and yearly after surgery. In addition, serial limb alignment measurements, ultrasonographic assessments of meniscal location and integrity, quantitative MRIs for cartilage composition, and serum and urine biomarkers for treatment monitoring will be performed. All complications and re-operations will be recorded. OCA survival will be determined based on maintenance of acceptable levels of pain and function and/or need for revision surgery or total knee arthroplasty.
Early mobilization started within 72 hours of ICU admission without the use of a robotic assistance. Mobilization is done by personell.
PURPOSE:To obtain the titled ink compsn. contg. a pigment stable for a long period of time and providing a film having improved physical properties, by dispersing a pigment in a thermoplastic resin and thereafter blending an ultraviolet-curing resin, a conductivity imparting agent, a photo-reaction initiator, and a solvent. CONSTITUTION:A pigment is dispersed in a thermoplastic resin. Thereafter the other essential components of an ultraviolet-curing resin, a pigment, a conductivity imparting agent, a photo-reaction initiator, and a solvent are added thereto. The pigment used may be any of an inorg. or org. one. The thermoplastic resin is used in an amt. of 20-200wt% of the pigment and dissolved by addn. of an org. solvent consisting essentially of pref. ketone or alcohol. The resulting soln. is placed in a dispersing means such as a ball mill to disperse the pigment so that it has a particle size of 3mu or less. The ultraviolet-curing resin is used in an amt. which is about 10-50wt% of the ink compsn., pref. with about 5-100wt% of that amt. being a tri- or more functional polyacrylate such as a triacrylate and a trimethacrylate.
Administer Kionex Suspension at least 3 hours before or 3 hours after other oral medications. Patients with gastroparesis may require a 6 hour separation (see WARNINGS and PRECAUTIONS, Drug Interactions).

The average daily adult dose is 15 g (60 mL) to 60 g (240 mL) of suspension. This is best provided by administering 15 g (60 mL) of Kionex Suspension one to four times daily. Each 60 mL of Kionex Suspension contains 1500 mg (65 mEq) of sodium. Since the in-vivo efficiency of sodium-potassium exchange resins is approximately 33%, about one-third of the resin’s actual sodium content is being delivered to the body.

In smaller children and infants, lower doses should be employed by using as a guide a rate of 1 mEq of potassium per gram of resin as the basis for calculation. Administer with patient in an upright position (see WARNINGS).

Kionex Suspension may be introduced into the stomach through a plastic tube and, if desired, given with a diet appropriate for a patient in renal failure.

Kionex Suspension may also be given, although with less effective results, as an enema consisting (for adults) of 30 g (120 mL) to 50 g (200 mL) every six hours. The enema should be retained as long as possible and followed by a cleansing enema.

After an initial cleansing enema, a soft, large size (French 28) rubber tube is inserted into the rectum for a distance of about 20 cm, with the tip well into the sigmoid colon, and taped into place. The suspension is introduced at body temperature by gravity. The suspension is flushed with 50 or 100 mL of fluid, following which the tube is clamped and left in place. If back leakage occurs, the hips are elevated on pillows or a knee-chest position is taken temporarily. The suspension is kept in the sigmoid colon for several hours, if possible. Then the colon is irrigated with a sodium-free cleansing enema at body temperature in order to remove the resin. Two quarts of flushing solution may be necessary. The returns are drained constantly through a Y tube connection. Particular attention should be paid to this cleansing enema, because sorbitol is present in the vehicle.

The intensity and duration of therapy depend upon the severity and resistance of hyperkalemia. Kionex Suspension should not be heated for to do so may alter the exchange properties of the resin.
The study was approved by the appropriate Institutional Review Board. Thirty ASA II-IV patients, undergoing elective or emergency surgery under general anaesthesia were included and randomized into three equal groups: ISO, SEVO or DES. We used MIRUS, a gas delivery system with a VA reflector, just like AnaConDa, that can be paired with common ICU ventilators. Additionally, MIRUS features the unique ability to maintain the end-tidal concentration (etVA) in target by automatically adjusting the delivery rate. Every 8 hours, the RASS was assessed by the nurse. The log of the EEG-Narcotrend Index (NI) was also included in the study.
PURPOSE:To obtain a water-based extract containing little precipitate and useful as pharmaceuticals and cosmetics, by extracting OUBAKU (bark of Phellodendron amurense) with a fatty acid ester to obtain a soluble component useful as an external drug for skin, and extracting the residue with a mixture of water and alcohol after defatting. CONSTITUTION:1pt. of OUBAKU is added to 2pts. of a fatty acid ester having a boiling point of >=80-100 deg.C, immersed at 80-100 deg.C, and separated into the layer of the fatty acid ester (A-layer) and the residue (B-layer). The A-layer is left at rest at -20+ or -5 deg.C, and filtered to obtain a liquid containing the component soluble in the fatty acid ester (A-liquid). Separately, the B-layer is defatted with n- hexane, and extracted with a 1:1 mixture of water and propylene glycol (or ethanol, etc.) at 60-100 deg.C. The obtained liquid layer is left at rest at -20+ or -5 deg.C, and filtered to obtain a water-soluble extract (B-liquid) having little flocculate and precipitate. The extract has moisturizing effect to the skin, and can be used as an external drug for skin.
Pregnancy Category D

Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death. Resulting oligohydramnios can be associated with fetal lung hypoplasia and skeletal deformations. Potential neonatal adverse effects include skull hypoplasia, anuria, hypotension, renal failure, and death. When pregnancy is detected, discontinue Lotensin HCT as soon as possible. These adverse outcomes are usually associated with use of these drugs in the second and third trimester of pregnancy. Most epidemiologic studies examining fetal abnormalities after exposure to antihypertensive use in the first trimester have not distinguished drugs affecting the renin-angiotensin system from other antihypertensive agents. Appropriate management of maternal hypertension during pregnancy is important to optimize outcomes for both mother and fetus.

In the unusual case that there is no appropriate alternative to therapy with drugs affecting the renin-angiotensin system for a particular patient, apprise the mother of the potential risk to the fetus. Perform serial ultrasound examinations to assess the intra-amniotic environment. If oligohydramnios is observed, discontinue Lotensin HCT, unless it is considered lifesaving for the mother. Fetal testing may be appropriate, based on the week of pregnancy. Patients and physicians should be aware, however, that oligohydramnios may not appear until after the fetus has sustained irreversible injury. Closely observe infants with histories of in utero exposure to Lotensin HCT for hypotension, oliguria, and hyperkalemia [see Precautions, Pediatric Use].

No teratogenic effects of Lotensin were seen in studies of pregnant rats, mice, and rabbits. On a mg/m2 basis, the doses used in these studies were 60 times (in rats), 9 times (in mice), and more than 0.8 times (in rabbits) the maximum recommended human dose (assuming a 50-kg woman). On a mg/kg basis these these multiples are 300 times (in rats), 90 times (in mice), and more than 3 times (in rabbits) the maximum recommended human dose. When hydrochlorothiazide was orally administered without benazepril to pregnant mice and rats during their respective periods of major organogenesis, at doses up to 3000 and 1000 mg/kg/day respectively, there was no evidence of harm to the fetus. Similarly, no teratogenic effects of benazepril were seen in studies of pregnant rats, mice, and rabbits; on a mg/kg basis, the doses used in these studies were 300 times (in rats), 90 times (in mice), and more than 3 times (in rabbits) the maximum recommended human dose.
Negative habits persist in contemporary society that can sometimes result in overweight or the deterioration of body image. This study aimed to assess the suitability of a nutritional and psychosocial intervention as part of an interdisciplinary approach to improve the perception of body image and increase the self-esteem of individuals who are overweight or obese. A total of 55 participants (25 men and 30 women) were included in this quasi-experimental intervention study. Measurements were taken as part of an ambulatory treatment to obtain values for weight, self-esteem, and body image perception using the Rosenberg scale and the Body Self-Esteem scale. At the end of the intervention and after one year, the weight reductions reached an average of 13.4 kg, positive self-image perception improved from a mean of 88.73 at pretest to 148.02 at follow-up, and self-esteem improved from a mean of 22.6 to 32.6. These were all statistically significant changes (p < 0.001). The model is effective in terms of weight reduction, together with improved levels of self-esteem and favorable perceptions of body image.
PURPOSE: The mortality rate for non-occlusive mesenteric ischemia remains high even after patients survive the acute postoperative period with tremendous treatment efforts, including emergency surgery, which is challenging. The aim of this study was to explore the preoperative risk factors for 90-day postoperative mortality in patients with non-occlusive mesenteric ischemia.
METHODS: This single-center, retrospective cohort study included patients diagnosed with non-occlusive mesenteric ischemia who underwent emergency surgery between August 2014 and January 2023. All patients were divided into survival-to-discharge and mortality outcome groups at the 90-day postoperative follow-up. Preoperative factors, including comorbidities, preoperative status of vital signs and consciousness, blood gas analysis, blood test results, and computed tomography, were compared between the two groups.
RESULTS: Twenty patients were eligible, and 90-day mortality was observed in 10 patients (50%). The mortality outcome group had significantly lower HCO3- (20.9 vs. 14.6, p = 0.006) and higher lactate (4.4 vs. 9.4, p = 0.023) levels than did the survival outcome group. The median postoperative time to death was 19 [2-69] days, and five patients (50%) died after postoperative day 30, mainly because hemodialysis was discontinued because of hemodynamic instability in patients requiring hemodialysis.
CONCLUSION: Low preoperative HCO3- and high lactate levels may be preoperative risk factors for 90-day postoperative mortality in patients with non-occlusive mesenteric ischemia. However, patients on hemodialysis die from discontinuing hemodialysis even after surviving the acute postoperative phase. Therefore, indications for emergency surgery in patients with risk factors for postoperative mortality should be carefully determined.
The present invention discloses a patient information confirmation assistant system, which is used in medical instruments, comprising: a storage module, a patient identification module, a processing module and a input/output module. The storage module is used to store the patient information, and each of the patient information includes at least one affected area information. The patient identification module is used to input the patient code information, and the patient code information corresponds to one of the plurality of patient information. The processing module receives the patient code information, and retrieves the corresponding patient information and affected area information accordingly. The input/output module is used to display the patient information and affected area information corresponding to the patient code information, output a questioning information accordingly, and is used to input the confirming information. Wherein the processing module determines the operation of the medical instrument operated by the user according to the patient information and affected area information which correspond to the patient code information, thus reduce the probability of medical malpractice.
PURPOSE:To prepare a homogeneous fine emulsion with low energy by mixing a nonionic surfactant with water and an oil phase component to form a micro- emulsion having a uniform single phase at 40-80 deg.C. CONSTITUTION:At least one kind of nonionic surfactant is mixed with water and an oil phase component to form a micro-emulsion having a uniform single phase at 40-80 deg.C. This micro-emulsion is instantaneously dispersed in water at a temp. below said temp. by >=20 deg.C and mixed to prepare an oil-in-water type emulsion. The pref. amt. of the surfactant contained in the micro-emulsion is 0.1-50wt.% and the pref. weight ratio of the oil phase component to water is 0.5/1-0.99/1. By this method, a large amt. of the homogeneous fine oil-in- water type emulsion can be produced with only a small quantity of heat energy.
All participants will receive induction chemotherapy and immunotherapy (every 3 weeks × 3 cycles of gemcitabine 1000 mg/m2 day 1, 8 + cisplatin 80 mg/m2 day 1 + camrelizumab 200 mg day 1) followed by conventional-dose intensity-modulated radiation therapy (IMRT; 6996cGy, 33 fractions, 5 fractions/week, 1 fraction/day). During the radiotherapy, all the participants will receive concurrent chemotherapy (every 3 weeks × 2 cycles of cisplatin 100 mg/m2 day 1). After 3 weeks of the completion of concurrent chemoradiotherapy, adjuvant camrelizumab (200 mg per cycle) will be administrated every 3 weeks for 9 cycles.
FIELD: organic chemistry, antibiotics, pharmacy. SUBSTANCE: invention describes macrolide of the formula (I):   or its tautomer, or solvate in crystalline form in each case. Invention describes also methods for preparing compound of the formula (I) in crystalline form and pharmaceutical composition designated for application as anti-inflammatory, immunosuppressive and antiproliferative agent. Invention provides preparing crystalline forms of compounds eliciting useful biological properties. EFFECT: improved preparing methods. 10 cl, 7 dwg, 1 tbl, 6 ex